XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 151 filers reported holding XENON PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 3.19 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,786,293 | -0.1% | 169,388 | +12.6% | 0.01% | 0.0% |
| Q2 2023 | $5,792,554 | +89.6% | 150,456 | +76.3% | 0.01% | +83.3% |
| Q1 2023 | $3,054,961 | -8.1% | 85,358 | +1.2% | 0.01% | -14.3% |
| Q4 2022 | $3,325,130 | -7.0% | 84,330 | -14.9% | 0.01% | -12.5% |
| Q3 2022 | $3,576,000 | +9.0% | 99,074 | -8.2% | 0.01% | +14.3% |
| Q2 2022 | $3,281,000 | +45.3% | 107,899 | +46.0% | 0.01% | +75.0% |
| Q1 2022 | $2,258,000 | +38.7% | 73,919 | +41.7% | 0.00% | +33.3% |
| Q4 2021 | $1,628,000 | +408.8% | 52,171 | +113.3% | 0.00% | +200.0% |
| Q4 2019 | $320,000 | -3.6% | 24,460 | -33.9% | 0.00% | 0.0% |
| Q3 2019 | $332,000 | -59.6% | 37,004 | -55.6% | 0.00% | -50.0% |
| Q2 2019 | $821,000 | +1646.8% | 83,280 | +1710.0% | 0.00% | – |
| Q1 2019 | $47,000 | +74.1% | 4,601 | +9.2% | 0.00% | – |
| Q4 2018 | $27,000 | – | 4,212 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
| ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
| BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
| Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
| COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
| DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
| Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
| Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
| KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
| Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |